share_log

Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $10

Benzinga ·  Oct 16, 2023 13:21

Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $15 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment